KR101107486B1 - 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 - Google Patents

티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 Download PDF

Info

Publication number
KR101107486B1
KR101107486B1 KR1020057013126A KR20057013126A KR101107486B1 KR 101107486 B1 KR101107486 B1 KR 101107486B1 KR 1020057013126 A KR1020057013126 A KR 1020057013126A KR 20057013126 A KR20057013126 A KR 20057013126A KR 101107486 B1 KR101107486 B1 KR 101107486B1
Authority
KR
South Korea
Prior art keywords
methyl
thieno
pyrimidine
methylethyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057013126A
Other languages
English (en)
Korean (ko)
Other versions
KR20050092760A (ko
Inventor
사이먼 데이비드 가일
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20050092760A publication Critical patent/KR20050092760A/ko
Application granted granted Critical
Publication of KR101107486B1 publication Critical patent/KR101107486B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020057013126A 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도 Expired - Fee Related KR101107486B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
SE0300119-5 2003-01-17
PCT/SE2004/000052 WO2004065394A1 (en) 2003-01-17 2004-01-15 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117022785A Division KR20110125256A (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Publications (2)

Publication Number Publication Date
KR20050092760A KR20050092760A (ko) 2005-09-22
KR101107486B1 true KR101107486B1 (ko) 2012-01-19

Family

ID=20290154

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057013126A Expired - Fee Related KR101107486B1 (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도
KR1020117022785A Withdrawn KR20110125256A (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117022785A Withdrawn KR20110125256A (ko) 2003-01-17 2004-01-15 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도

Country Status (23)

Country Link
US (2) US7384951B2 (https=)
EP (1) EP1587812B1 (https=)
JP (1) JP4519121B2 (https=)
KR (2) KR101107486B1 (https=)
CN (1) CN100334093C (https=)
AT (1) ATE335748T1 (https=)
AU (1) AU2004206012B2 (https=)
BR (1) BRPI0406801B8 (https=)
CA (1) CA2512441C (https=)
DE (1) DE602004001857T2 (https=)
EG (1) EG25613A (https=)
ES (1) ES2270337T3 (https=)
IL (1) IL169370A (https=)
IS (1) IS2376B (https=)
MX (1) MXPA05007496A (https=)
NO (1) NO333702B1 (https=)
NZ (1) NZ541217A (https=)
PL (1) PL214682B1 (https=)
RU (1) RU2331647C2 (https=)
SE (1) SE0300119D0 (https=)
UA (1) UA81788C2 (https=)
WO (1) WO2004065394A1 (https=)
ZA (1) ZA200505364B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
MXPA05007495A (es) * 2003-01-17 2005-09-21 Astrazeneca Ab Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
EP2411395B1 (en) * 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
WO2010109328A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
WO2013109972A2 (en) 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
PL3060562T3 (pl) * 2013-10-21 2022-01-10 Genosco Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk
CA2974697A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR101730536B1 (ko) * 2016-03-17 2017-05-02 주식회사 골프존 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체
KR101712838B1 (ko) * 2016-03-17 2017-03-07 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101712836B1 (ko) * 2016-03-17 2017-03-22 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CN119080799B (zh) * 2024-09-27 2025-12-05 山东大学 一种n-羟基噻吩并嘧啶二酮类衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012514A1 (en) * 1998-08-28 2000-03-09 Astrazeneca Ab Novel compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
WO1999029695A1 (en) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Novel compounds
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1280806B1 (en) * 2000-05-04 2004-08-04 AstraZeneca AB THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
MXPA05007495A (es) 2003-01-17 2005-09-21 Astrazeneca Ab Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012514A1 (en) * 1998-08-28 2000-03-09 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2004065394A1 (en) 2004-08-05
CN1761672A (zh) 2006-04-19
NZ541217A (en) 2008-05-30
RU2005121494A (ru) 2006-02-10
ZA200505364B (en) 2006-09-27
MXPA05007496A (es) 2005-09-21
CA2512441C (en) 2012-01-03
DE602004001857T2 (de) 2007-05-24
IL169370A (en) 2011-05-31
JP4519121B2 (ja) 2010-08-04
RU2331647C2 (ru) 2008-08-20
CN100334093C (zh) 2007-08-29
NO20053826L (no) 2005-10-17
EP1587812A1 (en) 2005-10-26
AU2004206012B2 (en) 2007-06-14
PL378222A1 (pl) 2006-03-20
IS7965A (is) 2005-07-29
NO333702B1 (no) 2013-08-26
IL169370A0 (en) 2007-07-04
UA81788C2 (uk) 2008-02-11
ATE335748T1 (de) 2006-09-15
IS2376B (is) 2008-07-15
EP1587812B1 (en) 2006-08-09
EG25613A (en) 2012-03-22
ES2270337T3 (es) 2007-04-01
JP2006516974A (ja) 2006-07-13
DE602004001857D1 (de) 2006-09-21
SE0300119D0 (sv) 2003-01-17
US7384951B2 (en) 2008-06-10
BRPI0406801A (pt) 2006-01-17
PL214682B1 (pl) 2013-09-30
KR20110125256A (ko) 2011-11-18
NO20053826D0 (no) 2005-08-15
HK1081959A1 (en) 2006-05-26
US20060052400A1 (en) 2006-03-09
AU2004206012A1 (en) 2004-08-05
BRPI0406801B8 (pt) 2021-05-25
KR20050092760A (ko) 2005-09-22
US20080214579A1 (en) 2008-09-04
BRPI0406801B1 (pt) 2018-04-03
CA2512441A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
KR101107486B1 (ko) 티에노피리미딘디온 및 그들의 자가면역 질환 조절 용도
AU2005214379B2 (en) Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
KR100897469B1 (ko) 티에노피리미딘디온 및 그의 자가면역 질환의 조절에있어서의 용도
US6300334B1 (en) Thieno[2,3-d]pyrimidine-2,4-diones
JP2004537557A (ja) 化学化合物
KR20050092759A (ko) 신규 화합물
US20080221131A1 (en) Thienopyrimidinediones and their use in modulation of autoimmune disease
HK1081959B (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
CN100354282C (zh) 噻吩并哒嗪酮及其在调节自身免疫疾病中的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20141231

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20151217

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161220

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20181226

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210112

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210112